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Abstract 
The presence of a microenvironment within most tumours containing regions of low oxygen 
tension or hypoxia has profound biological and therapeutic implications. Tumour hypoxia is 
known to promote the development of an aggressive phenotype, resistance to both 
chemotherapy and radiotherapy and is strongly associated with poor clinical outcome. 
Paradoxically, it is recognised as a high priority target and one therapeutic strategies 
designed to eradicate hypoxic cells in tumours are a group of compounds known collectively 
as hypoxia activated prodrugs (HAPs) or bioreductive drugs. These drugs are inactive 
prodrugs that require enzymatic activation (typically by 1 or 2 electron oxidoreductases) to 
generate cytotoxic species with selectivity for hypoxic cells being determined by (i) the ability 
of oxygen to either reverse or inhibit the activation process and (ii) the presence of elevated 
expression of oxidoreductases in tumours. The concepts underpinning HAP development 
were established over 40 years ago and have been refined over the years to produce a new 
generation of HAPs that are under preclinical and clinical development. The purpose of this 
article is to describe current progress in the development of HAPs focusing on the 
mechanisms of action, preclinical properties and clinical progress of leading examples.  
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Introduction 
One of the characteristic features of solid tumour biology is the presence of a poor and 
inadequate blood supply [1]. This leads to the establishment of microenvironments that are 
characterised by gradients of oxygen tension, nutrients, extracellular pH, catabolites and 
reduced cell proliferation all of which vary as a function of distance from a supporting blood 
vessel (figure 1). These microenvironments can be chronic in nature caused by poor blood 
supply (diffusion limited) or acute caused by the temporal opening and closing of blood 
vessels (perfusion limited). Hypoxia in tumours has been the focus of intense research for 
over 60 years and both diffusion and perfusion limited hypoxia are established features of 
solid tumours [2]. A third mechanism to explain the induction of hypoxia in tumours has been 
described, namely longitudinal arteriole gradients whereby oxygen rich inflowing blood 
vessels branch and coalesce to form poorly oxygenated outflowing blood [3]. In this model 
hypoxia would be formed along the axis of the vessel over a multi-millimetre range, which 
contrasts with the sub-millimetre distances typically associated with perfusion, and diffusion 
limited hypoxia. The origins of tumour hypoxia are therefore linked to the abnormal vascular 
supply that develops within tumours and there is a substantial body of evidence 
demonstrating that hypoxia is a common feature of most if not all-solid tumours.  
 
The presence of hypoxia in tumours has significant biological and therapeutic implications. 
Biologically, hypoxia is implicated in promoting resistance to apoptosis [4], suppression of 
DNA repair pathways and promotion of genomic instability [5] increased invasion and 
metastasis [6], promotion of angiogenesis [7], modulation of tyrosine kinase mediated cell 
signalling pathways [8], evasion from immune surveillance [9], induction of autophagy [10], 
hypoxia driven changes in central metabolic pathways [11], global changes in the 
metabolome [12], production of L-2-hydroxyglutarate leading to altered histone methylation 
[13], metabolic adaptation to hypoxia induced reductive stress [14] and the provision of a 
niche where cancer stem cells reside [15]. The plethora of effects on tumour biology is 
mediated largely by hypoxia inducible factors (HIF) [16] although HIF1 independent hypoxia 
responses have also been described [17]. In terms of therapeutic implications, the seminal 
work conducted by Gray in the 1950’s [18] provided the first evidence that hypoxia is an 
underlying cause of resistance to radiotherapy.  Since then, hypoxia has been strongly 
implicated in resistance to several cytotoxic chemotherapy drugs and targeted therapeutics 
[19,20]. Multiple mechanisms contribute to hypoxia induced drug resistance but as pointed 
out by Wilson and Hay however [21], the generalisation that hypoxia causes resistance to all 
cytotoxic drugs must be viewed with caution as some drugs are effective under hypoxic 
conditions. This note of caution should also be extended to include targeted therapeutics 
following the demonstration that some (such as dasatinib) are preferentially active against cell 
lines in vitro under hypoxic conditions [22]. 
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Whilst the extent and severity of hypoxia in tumours varies between tumour types and within 
individual tumours, the combined biological and therapeutic implications of hypoxia have a 
significant bearing on prognosis. There is now an extensive body of evidence demonstrating 
that hypoxia can adversely affect clinical outcome [23,24] and this makes hypoxia a high 
priority therapeutic target. The importance of hypoxia as a target has been recognised for 
many years but the translation of preclinical strategies designed to target hypoxic cells into 
mainstream clinical use has remained stubbornly difficult to achieve. Two main approaches 
are being used to eradicate hypoxic cells (i) the use of ‘bioreductive drugs’ or ‘hypoxia 
activated pro-drugs (HAPs)’ and (ii) molecularly targeted drugs aimed at exploiting 
biochemical responses to hypoxia, particularly HIF pathways. The current status of HIF 
targeted strategies is beyond the scope of this article which focuses on HAPs, their 
mechanism of action and recent progress in the preclinical and clinical evaluation of leading 
compounds in this class of drugs. This article also describes novel approaches where HAP 
based approaches are being used to improve the selectivity of targeted therapeutics.  
 
Hypoxia Activated Prodrugs (HAPs): General principles 
The concept of hypoxia activated prodrugs arose largely from the seminal work on quinone 
based derivatives of Mitomycin C by Alan Sartorelli in the early 1970’s [25]. Initially these 
early studies focused primarily on enzyme activated prodrugs in a process called bioreductive 
activation under aerobic conditions but this concept was extended to include hypoxia 
following the demonstration that Mitomycin C preferentially killed hypoxic cells in vitro [26]. 
Over recent years the term HAPs has become established but HAPs and bioreductive drugs 
are terms that are often used interchangeably. The principles underpinning the development 
of HAPs has been refined over the years and the ‘ideal HAP’ should possess the following 
properties (i) ability to penetrate from a blood vessel to hypoxic cells within its 
pharmacokinetic lifespan; (ii) preferential activation oxygen conditions that are low enough to 
prevent activation in normal tissues; (iii) the reduced product should have the ability to kill 
non-proliferating cells typically found within the hypoxic fraction of tumours; (iv) the reduced 
product should have the ability to diffuse back into the proliferating aerobic fraction and exert 
a ‘bystander effect’ (figure 1).  
 
Five different chemical entities have been shown to be capable of selectively targeting 
hypoxic cells and these include nitro (hetero) cyclic compounds, aromatic N-oxides, aliphatic 
N-oxides, quinone and transition metal complexes [27]. Whilst these are chemically distinct 
classes of compounds, a modular concept for the design of HAPs has been described with 
the three main components being (i) a trigger; (ii) a linker and (iii) an effector [28]. The 
effector is the cytotoxic component that is capable of killing cells within the hypoxic 
microenvironment and these have typically been potent DNA interactive agents. The purpose 
of the linker is to deactivate the effector whilst the trigger group is the critical group that 
determines pro-drug activation and hypoxia selectivity. Numerous trigger groups have been 
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characterised and these have to be enzymatically reduced (primarily by oxidoreductases) in 
order to release or activate the effector [28]. Both one and two electron oxidoreductases can 
catalyse the reduction of the pro-drug and selectivity is determined by the ability of oxygen to 
reverse the activation process and/or the overexpression of oxidoreductases in tumour tissue 
(figure 1). In general terms, one electron reduction generates a pro-drug radical species that 
can be back oxidised in the presence of oxygen to generate the parental pro-drug and 
reactive oxygen species. Host defence mechanisms can detoxify these radical species 
thereby reducing toxic effects in oxygenated tissue but in the absence of oxygen, the pro-drug 
radical species undergoes further reduction / disproportionation or fragmentation reactions to 
generate products that are cytotoxic [21] Two-electron reduction in contrast bypasses the 
oxygen sensitive pro-drug radical intermediate and activation of the pro-drug is typically 
oxygen insensitive. In this case, selectivity is largely determined by the presence of elevated 
levels of enzyme in tumour tissue [29]. The mechanisms governing hypoxia activated pro-
drug activation are summarised in figure 1 and important exceptions to these generalised 
mechanisms are identified here and in the main body of text below. It is also important to 
state that hypoxia directed therapeutic agents are unlikely to demonstrate single agent activity 
and should be used in combination with radiotherapy and/or chemotherapy that target aerobic 
cells. Furthermore, in order to become effective components of combination therapies HAPs 
need to be sufficiently safe with minimal side effects.  
 
Whilst the concepts underpinning bioreductive drug and HAP activation are elegant and 
simple, success in this field has been very difficult to achieve and the stark reality is that 
despite over 40 years of pre-clinical and clinical research, no HAP has so far been approved 
for use in humans. Despite this lack of success, important lessons have been learnt from 
preclinical and clinical studies that have helped shape the design and evaluation of new 
HAPs. There is currently considerable optimism in the field and in the following sections, 
recent progress in the pre-clinical and clinical evaluation of a series of selected HAPs (figure 
2) is presented together with some emerging strategies for the next generation of HAPs.  
 
TH-302 (Evofosfamide): 
TH-302 is a 2-nitroimidazole HAP of bromo-isophosphoramide, the synthesis and initial 
preclinical evaluation of which was published in 2008 [30]. It was discovered by Threshold 
Pharmaceuticals and TH-302 is currently being developed in partnership with Merck. Its 
preclinical pharmacology has been described in detail elsewhere [31]. Its mechanism of 
action is presented in figure 3 and key features of its pharmacology include (i) reduction by 
one electron oxidoreductases or radiolytic reduction leading to fragmentation and release of 
the potent DNA alkylating agent bromo isophosphoramide mustard; (ii) hypoxia dependent 
induction of γH2AX, DNA cross linking and cell cycle arrest; (iii) broad activity against a range 
of cell lines with hypoxic cytotoxicity ratios (HCR) ranging from 11 to 600; (iv) cells deficient in 
homology dependent DNA repair, BRCA1, BRCA2 and FANCA exhibited marked sensitivity 
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to TH-302 under hypoxia; (v) enhanced potency against H460 multicell spheroids compared 
to monolayer cultures; (vi) exhibited a bystander effect in in vitro mulitcell layer models and in 
vivo; (vii) broad anti-tumour activity across a panel of human tumour xenografts with clear 
evidence of selective eradication of hypoxic cells and neighbouring cells via the bystander 
effect and (viii) good pharmacokinetic and safety profiles in mice, rats, dogs and monkeys. 
More recent studies have confirmed that TH-302 targets hypoxic cells and potentiates the 
activity of doxorubicin and docetaxel in human tumour xenografts [32] and its activity in vivo 
can be enhanced by the induction of transient hypoxia [33]. As part of a combination regimen 
with cytotoxic drugs, targeted therapeutics or radiotherapy, TH302 has been shown to 
enhance anti-tumour activity and reduce the ability of hypoxic cells to repopulate tumours 
following re-oxygenation [34-40]. Activity is not confined to solid tumours but extends to acute 
myeloid leukaemia where TH-302 was effective against hypoxic cells that reside within the 
bone marrow microenvironment [41].   
 
TH-302 is undergoing clinical trial and phase I studies were published in 2011 [42,43]. As a 
single agent administered intravenously, TH-302 was well tolerated. At the maximum 
tolerated doses, adverse events included nausea, skin rash, fatigue and vomiting and 
depending on the regimen used, dose limiting toxicities were grade 3 skin and mucosal 
toxicities or grade 3 fatigue and vaginitis/proctitis [43]. Two partial responses in patients with 
metastatic small cell lung cancer and melanoma were observed with stable disease seen in 
27 out of 57 patients [43]. A phase I study of TH-302 in combination with doxorubicin 
demonstrated that despite the hematologic toxicity of doxorubicin increasing when combined 
with TH-302, toxicities were manageable and partial responses were observed in 5 out of 15 
patients with advanced soft tissue sarcoma [42]. Furthermore, one patient with advanced 
melanoma participating in the phase I studies had complete resolution of Cullen’s sign 
together with extra-cranial response in lung, liver and lymph node metastasis [44]. Promising 
clinical activity has also been reported in phase II trials involving TH-302 in combination with 
doxorubicin in advanced soft tissue sarcoma [45] and in combination with gemcitabine in 
patients with advanced pancreatic cancer [46]. TH-302 is undergoing further phase II trials 
against Non-Small Cell Lung Cancer (with pemetrexed, NCT02093962) and advanced 
melanoma (NCT01864538) and phase III clinical trials against soft tissue sarcoma 
(NCT01440088) and pancreatic cancer (NCT01746979, MAESTRO study) are on-going. The 
results of phase III studies are eagerly anticipated.  
 
EO9 (Apaziquone): 
EO9 is an indolequinone derivative of Mitomycin C that was originally synthesised in 1987 at 
the University of Amsterdam [47]. It has a chequered history, details of which have been 
reviewed recently [48]. Its mechanism of action (figure 4) involves reduction by one and/or 
two electron oxidoreductases to generate DNA damaging species both in aerobic and hypoxic 
conditions. The two electron reductase NAD(P)H:Quinone oxidoreductase 1 (NQO1 or DT-
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diaphorase) plays a central role in the bioreductive activation process and largely determines 
its ability to target aerobic or hypoxic cells [29]. EO9 has the ability to function as a classical 
HAP but only in cell lines that have low or no NQO1 [49,50]. Under these conditions, one 
electron reduction by enzymes such as cytochrome P450 reductase generates the semi-
quinone radical which can redox cycle back to the parent compound in the presence of 
oxygen. HCR values in excess of 100 have been reported in a number of cell lines but 
particularly marked hypoxia selectivity occurs in cell lines that harbour the C609T single 
nucleotide polymorphism that is devoid of NQO1 activity [49,51]. In cell lines with high NQO1 
however, the oxygen insensitive two-electron reduction pathway dominates and HCR values 
close to 1 are typically reported [50]. In these cell lines, a good correlation between NQO1 
activity and chemosensitivity under aerobic conditions exist [50]. Preclinical studies therefore 
demonstrated that EO9 has the ability to target both the aerobic fraction of NQO1 rich 
tumours (where selectivity is determined by elevated levels of NQO1 in tumours) and the 
hypoxic fraction of NQO1 deficient tumours [29]. 
 
Based on these and other favourable preclinical properties [52], EO9 was selected for clinical 
evaluation under the auspices of the New Drug Development Office in Amsterdam with phase 
I studies reporting partial responses in two patients with carcinomas of unknown origin and 
one in bile duct cancer [53,54]. The results of phase II studies were however disappointing 
with no partial or complete responses observed. These studies concluded that EO9 had no 
clinical activity against NSCLC, pancreatic, breast, colorectal, and gastric cancer [55,56]. 
Several possible explanations were put forward to explain the poor results of these studies 
including the fact that EO9 was not evaluated as a classical HAP as it was only tested as a 
single agent. Furthermore, tumour enzymology and the presence of hypoxia in patient’s 
tumours were not incorporated into the design of the trials [57]. Whilst these issues represent 
important deficiencies in clinical trial design, it was argued that at least some patients would 
have had the right ‘biochemical machinery’ to activate EO9 and other explanations for why 
EO9 failed must exist.  
 
Research focused on the issue of impaired drug delivery to tumours as a possible 
explanation. Whilst the factors that determine drug delivery to tumours are complex, systemic 
pharmacokinetic profiles and the ability to extravasate and penetrate through several layers of 
tumour cells to reach the hypoxic fraction are two key parameters [58]. Phase I studies had 
already established that EO9 was rapidly cleared from the systemic circulation following 
intravenous administration with half-lives of less than 20 min [54]. This combined with 
experimental evidence demonstrating that EO9 does not rapidly penetrate multicell layers in 
vitro suggested that EO9 will not penetrate more than a few cell layers from a blood vessel 
within its pharmacokinetic lifespan [59]. One method pursued to tackle this problem was to 
develop analogues of EO9 with better drug delivery properties but an alternative approach 
designed to use EO9’s bad properties to our advantage was adopted. In the case of 
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superficial transitional cell carcinoma of the bladder, chemotherapy is administered directly 
into the bladder by a catheter (intravesical administration). Intravesical administration of EO9 
into the bladder would (i) circumvent the drug delivery problem observed following 
intravenous administration; (ii) retention within the bladder for up to one hour would extend 
the time EO9 was in contact with the tumour and enhance penetration and (iii) any drug that 
reached the systemic circulation would be rapidly cleared thereby reducing the risk of 
systemic toxicity. 
 
Following the demonstration that superficial transitional cell carcinoma of the bladder 
possessed the correct biochemical machinery required to activate EO9 [60] a new clinical trial 
was developed. Spectrum Pharmaceuticals sponsored the phase I study and EO9 was 
administered directly into the bladder (intravesical administration) once a week for 6 weeks 
followed by assessment of anti-tumour efficacy two weeks after the final instillation. Prior to 
the administration of EO9, patients with multiple tumour lesions had all but one tumour 
surgically removed with the remaining tumour left to serve as a ‘marker lesion’ for assessing 
response. Complete response was defined as total ablation of the marker lesion and 8 
complete responses were obtained out of a total of 12 patients entered into the study [61]. 
Using an identical trial design, similar complete response rates (30 out of 45 patients) were 
reported in phase II studies [62] and recurrence-free rates at two years were good in 
comparison with other marker lesion studies [63,64]. Following the demonstration that a 
single intravesical administration of EO9 within 24 hours of transurethral resection was well 
tolerated with a good safety profile [65], two phase III trials commenced using this new 
administration schedule (NCT00598806 and NCT00461591). In April 2012, Spectrum 
Pharmaceuticals announced that the results of these two trials did not meet their primary 
endpoint of a statistically significant difference in the rate of tumour recurrence at two years 
but analysis of the pooled data from both studies showed a statistically significant effect in 
favour of EO9. A further phase III study using a multi-instillation schedule (once a week for 6 
weeks) has been planned (NCT01410565).   
 
AQ4N (Banoxantrone): 
AQ4N is an aliphatic N-oxide that is metabolised by cytochrome P450 (CYP) isozymes and 
inducible nitric oxide synthase (iNOS) to AQ4, a potent inhibitor of topoisomerase II [66,67]. 
Its mechanism of action is summarised in figure 5 and involves an initial two electron 
reduction step to the mono-N-oxide (AQ4M) followed by a further two electron reduction to 
generate AQ4. Selectivity for hypoxic cells occurs because oxygen outcompetes AQ4N for 
the haem-centred active site of CYPs and oxygen therefore effectively inhibits the reduction 
of AQ4N [68]. Activation not only occurs in tumour cells but also in hypoxic tumour associated 
macrophages where the induction of iNOS under hypoxic conditions led to reduction of AQ4N 
and killing of tumour cells via a bystander effect [69]. One of the key features of its 
mechanism of action is that AQ4 is a stable reduction product that strongly binds non-
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covalently to the DNA of hypoxic cells. Following the eradication of aerobic cells by 
radiotherapy and/or chemotherapy, hypoxic cells undergo a period of re-oxygenation and can 
repopulate the tumour. AQ4 inhibits the topoisomerase activity of hypoxic cells as they 
attempt to re-enter the cell cycle during these periods of re-oxygenation and in preclinical 
models in vivo, AQ4N in combination with radiotherapy substantially enhances anti-tumour 
efficacy [70,71]. Similar effects were seen with combinations of AQ4N and thiotepa, 
cyclophosphamide, cisplatin and the structurally related drug mitoxantrone [72,71,73]. More 
recent studies have demonstrated that the use of AQ4N following androgen deprivation 
therapy using bicalutamide (which induces hypoxia in tumours) significantly improves 
treatment outcome in prostate cancer xenografts [74]. Similarly, recent studies have also 
demonstrated that AQ4N has anti-metastatic properties by targeting hypoxic lesions in the 
lymph nodes and lymphatics in xenograft models [75]. With regards to drug delivery to the 
hypoxic fraction, studies in tumour models in vivo demonstrate that AQ4N has the ability to 
penetrate into hypoxic regions of tumour [73,76]. Taken together, the preclinical profile of 
AQ4N clearly illustrates its potential as a HAP that is capable of tackling the key issue of 
tumour repopulation by hypoxic cells following the eradication of the aerobic fraction by 
conventional radio/chemotherapy. In addition to its HAP properties, AQ4N has also been 
shown to have anti-angiogenic properties under aerobic conditions, selectively targeting 
endothelial cells at low doses, inhibiting migration, tube formation, aortic ring vessel sprouting 
and invasion of proliferating endothelial cells [77]. Whilst the mechanism of action responsible 
for its anti-angiogenic properties is not fully understood (significant disruption of microtubule 
networks was observed), this mechanism could potentially contribute to the anti-tumour 
activity of AQ4N.   
 
AQ4N has undergone clinical evaluation and three phase I studies have been reported, two of 
which have evaluated AQ4N as a single agent [78,79] and one in combination with 
radiotherapy [80]. As a single agent, AQ4N was well tolerated up to a maximum tolerated 
dose of 768 mg/m2 (administered intravenously as a 30 min infusion on days 1, 8 and 15 of a 
28 day cycle) with the most common adverse events being fatigue, diarrhoea, nausea, 
vomiting, anorexia and blue discolouration of skin and body fluids [79]. The pharmacokinetic 
profile of AQ4N was dose dependent with low levels of AQ4M and no AQ4 detected in the 
systemic circulation. Three patients had stable disease, two with bronchoalveolar lung cancer 
and ovarian cancer and the third with collecting duct renal cancer had prolonged stable 
disease for 25 months [79]. In a phase I proof of principle pharmacodynamics study, AQ4N at 
a dose of 200mg/m2 (single dose administered intravenously using a 30 min infusion) was 
administered 12 to 36 hours before multiple samples of tumour and normal tissue were 
surgically removed from each patient. AQ4N and its metabolites were analysed by LC/MS, 
the distribution of AQ4 relative to blood vessels determined by confocal microscopy and the 
relationship between AQ4 levels and the expression of the endogenous hypoxia marker Glut-
1 determined by immunohistochemistry [78]. This study demonstrated that AQ4N was 
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activated selectively in hypoxic regions of solid tumours and the levels of AQ4 detected 
exceeded those required for activity in animal models. In addition, high levels of AQ4 were 
detected in glioblastoma multiforme indicating that AQ4N effectively crossed the blood brain 
barrier [78]. In combination with radiotherapy, AQ4N was well tolerated up to 447 mg/m2 
administered intravenously with no dose limiting toxicity and tumour AQ4 concentrations also 
exceeded levels required for activity in preclinical models. Of the eighteen patients that were 
assessable for response one had a partial response, two had >50% tumour volume reduction 
and nine patients had stable disease [80]. Whether these responses were due to AQ4N or 
radiotherapy alone was not possible to determine but the results of this study illustrates the 
potential value of combination studies of AQ4N with radiotherapy. Regrettably, the clinical 
development of AQ4N has stalled but it is hoped that further clinical studies will take place in 
the future. 
 
PR-104: 
PR-104 is a nitroaromatic compound that is a water-soluble phosphate ester ‘pre-prodrug’ of 
PR-104A, originally developed by the University of Auckland [81]. Its mechanism of action 
has been described in detail elsewhere [27] and is summarised in figure 6. Briefly, PR-104 
undergoes rapid hydrolysis by systemic phosphatases to generate PR-104A that is 
metabolised by one and/or two electron oxidoreductases to the para-hydroxylamine PR-104H 
and para-amine PR-104M metabolites resulting in interstrand DNA cross linking. Various 
oxidoreductases have been shown to catalyse the reduction of PR-104A including 
cytochrome P450 reductase [82], FAD-dependent oxidoreductase domain containing 2 
(FOXRED2, [83]) and aldo-ketoreductase 1C3 (AKR1C3) [84]. PR-104 can target both 
hypoxic and aerobic cells with one electron reduction pathways catalysed by cytochrome 
P450 reductase accounting for the majority of activity under hypoxia [85]. Reduction by 
AKR1C3 (oxygen insensitive two electron reduction process) accounts for activity under 
aerobic conditions [84]. Hypoxia selectivity in vitro is governed by the fact that the product of 
one electron reduction undergoes redox cycling back to the parent compound and hypoxia 
together with reductase activity and repair of DNA inter-strand cross links are key variables 
that determine response to PR-104 [86]. More recent studies have also demonstrated that 
PR-104 is particularly active against hypoxic regions of triple negative breast cancers that 
have dysfunctional homologous recombination repair pathways [87].  
 
PR-104 has activity against a range of in vivo preclinical models and its properties means it 
can target hypoxic tumours and/or the aerobic fraction of tumours expressing AKR1C3. 
Against T-cell acute lymphoblastic leukaemia xenografts, single agent PR-104 treatment 
proved more efficacious compared to a combination of vincristine, dexamethasone and L-
asparaginase and activity correlated with AKR1C3 expression [88]. This study also concludes 
that AKR1C3 expression could be used as a biomarker to select patients most likely to benefit 
from PR-104 treatment in future clinical trials. Similar studies reported complete responses in 
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acute lymphoblastic leukaemia models and objective responses in other solid tumours but in 
contrast, tumour response did not correlate with AKR1C3 levels [89]. Other studies have 
demonstrated that PR-104 could be used to eradicate acute lymphoblastic leukaemia cells 
residing in hypoxic niches in the bone marrow [90]. Against solid tumours, experimental and 
in silico modelling demonstrate that PR104/PR104A is able to penetrate into severely hypoxic 
regions of tumours where it is preferentially metabolised to cytotoxic metabolites [91]. A 
combination of experimental and modelling techniques have also demonstrated that PR-104A 
can exert a bystander effect that is predicted to contribute significantly to the anti-tumour 
efficacy of PR-104 [92]. PR-104 has demonstrated anti-tumour activity as a single agent 
against a range of solid tumour xenografts and greater than additive effects have been 
reported when PR-104 is used in combination with chemotherapy agents such as 
gemcitabine, docetaxel and sorafenib [93,81] and/or radiotherapy [87]. The use of 
pharmacological approaches to induce tumour hypoxia has also been shown to potentiate the 
activity of PR-104 [94].   
 
PR-104 is undergoing clinical trials and several phase I clinical trials have been completed. 
As a single agent a maximum tolerated doses of 1,100 mg/m2 was reported following a one 
dose every 21 days schedule [95] and 675 mg/m2 when given on a one dose per week for 3 
weeks schedule [96]. In both studies PR-104 administered by a one-hour intravenous 
infusion. Dose limiting toxicities included fatigue, febrile neutropenia, infection following the 
once a week every 21 days schedule and thrombocytopenia and to a lesser extent 
neutropenia using the more intensive schedule [95,96]. No objective responses were reported 
in these studies despite the fact that PR-104A plasma AUC values exceeded the levels 
required for activity in preclinical models [95]. In combination with either gemcitabine or 
docetaxel severe dose limiting myelotoxicity occurred, the impact of which was reduced by 
prophylactic G-CSF in the case of docetaxel [97]. A combination of PR-104 and sorafenib in 
advanced hepatocellular carcinoma was also poorly tolerated with significant 
thrombocytopenia and neutropenia reported [98]. PR-104A undergoes glucoronidation [99] 
and it was suggested that reduced clearance due to compromised glucoronidation in patients 
with advanced hepatocellular carcinoma of PR-104A was partly responsible for the toxicity 
observed [98]. Recent studies in mice that do not significantly glucoronidate PR-104A confirm 
that the development of analogues of PR104 that are not readily glucoronidated may be able 
to exploit elevated AKR1C3 and/or hypoxia in hepatocellular carcinoma in humans [93]. 
Based on strong preclinical data, a phase I/II study in acute myeloid leukaemia (AML) and 
acute lymphoblastic leukaemia (ALL) has demonstrated clinical activity in 10 out of 31 
patients with AML and 2 out of 10 patients with ALL [100]. PR-104 treatment also decreased 
the number of hypoxic cells in the bone marrow. These positive results indicate that PR-104 
is able to exploit the hypoxic niche in acute leukaemias and further clinical evaluation in this 
setting is warranted.  
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Tirapazamine (TPZ): 
TPZ is an aromatic N-oxide that was originally developed in the mid 1980’s and its 
pharmacological properties have been extensively reviewed elsewhere [21]. Its mechanism of 
action is summarised in figure 7 and briefly, TPZ is reduced by one electron reductases (such 
as cytochrome P450 reductase) to generate a radical species which in the absence of oxygen 
undergoes further spontaneous reactions leading to the formation of DNA damaging oxidising 
hydroxyl or benzotriazinyl radicals [101]. Selectivity for hypoxic cells is determined by the 
ability of oxygen to reverse the one electron reduction step resulting in back oxidation to the 
parent compound and the formation of superoxide. The two-electron reductase NQO1 can 
also reduce TPZ but this is considered a bioprotective mechanism as it by passes the TPZ 
radical and forms the relatively non-toxic mono N-oxide [102]. High hypoxia selectivity has 
been reported in a number of cell lines and in vivo studies demonstrated that TPZ in 
combination with radiotherapy and cisplatin was highly effective against a range of human 
tumour xenografts [103] and TPZ entered clinical trial in early 1990’s.  
 
TPZ has been extensively evaluated in the clinic.  Both phase I and II studies generated 
positive results, particularly phase II studies where TPZ was used in combination with 
cisplatin, etoposide and/or radiotherapy [104-107]. Unfortunately, several phase III clinical 
trials have failed to demonstrate any survival advantage by adding TPZ to chemotherapy or 
radiotherapy in non-small cell lung cancer [108], head and neck cancer [109] and cervical 
cancer [110]. Reasons for the failure of TPZ include failure of radiotherapy protocol 
compliance and lack of stratification of patients based on tumour hypoxia levels [111,112]. 
Subsequent sub-group analysis of these trials using a range of endogenous markers of 
hypoxia proved of limited benefit in both head and neck cancer and NSCLC trials [113-115]. 
Whilst better methodologies for measuring hypoxia could have been employed [116,117], the 
lack of a correlation between clinical response and hypoxia markers supports the clinical 
findings that inclusion of TPZ into combination protocols has limited if any clinical benefit. An 
alternative explanation for the failure of TPZ is relatively poor drug penetration into hypoxic 
regions of tumours. Because TPZ can be activated under comparatively mild hypoxia, it has 
been shown that TPZ is metabolised too rapidly to penetrate deeply into severely hypoxic 
tissue [118]. Using a combination of in silico models and experimental approaches, 
analogues of TPZ that have better penetration and metabolism properties have been 
developed with SN30000 (now known as CEN-209 following licencing to Centella) emerging 
as a candidate for clinical development [119]. Details of its mechanism of action have been 
described elsewhere [120] and SN30000 is likely to proceed to Phase I clinical trials shortly. It 
is hoped that the valuable experience gained from the TPZ clinical trials are incorporated into 
the design of these trials [111].  
 
 
 
 12 
TH-4000: 
The vast majority of HAPs developed to date result in the generation of metabolites that 
damage DNA either directly or indirectly. TH-4000 represents a significant departure from this 
mechanism and is one of the first hypoxia activated molecularly targeted therapeutic to be 
developed. Discovered at the University of Auckland and initially referred to as PR-610 or 
HypoxinTM, TH-4000 is a hypoxia activated EGFR tyrosine kinase inhibitor (TKI) that is now 
being developed by Threshold Pharmaceuticals. It is designed to release an irreversible 
EGFR TKI within hypoxic regions of tumours (figure 8) thereby improving selectivity and 
circumventing some of the toxicities observed with existing EGFR TKIs. Preclinical studies 
have been published in abstract form [121,122] where TH-4000 was shown to be more active 
against NSCLC xenografts with wild type and mutant EGFR than Erlotinib. TH-4000 is 
currently undergoing phase II clinical evaluation against EGFR mutant, T790M negative 
patients with advanced NSCLC (NCT02454842) and metastatic squamous cell carcinoma of 
the head and neck or skin (NCT02449681).  
 
Novel HAPs in preclinical development  
Whilst HAPs designed to release DNA damaging species are still being developed other 
HAPs have been designed to release inhibitors of DNA damage response pathways 
[123,124]. Release of the Chk1/Aurora A inhibitor CH-01 (figure 9) following reduction of a 4-
nitrobenzyl hypoxia trigger leads to fragmentation and release of active Chk1/Aurora A 
inhibitor with potent activity against severely hypoxic cells in vitro [123]. Similarly, attachment 
of a DNA-PK inhibitor to a nitroimidazole hypoxia trigger group led to inactivation of the 
complex (BCCA621C, figure 9) and no cytotoxic activity under aerobic conditions was 
reported [124]. Under severe hypoxia however, the inhibitor was released and was able to 
radiosensitize hypoxic H460 cells in vitro with a sensitizer enhancement ratio of 1.85. HAPs 
targeting the O6-alkylguanine DNA alkyltransferase (AGT, figure 9) pathway have also been 
developed and have shown hypoxia selective activity in a range of cell lines in vitro [125]. 
This approach could lead to the selective depletion of AGT in tumour tissue without 
corresponding depletion in normal tissue leading to sensitization of tumours to O6 guanine 
targeting cytotoxic drugs such as temozolomide. Using a similar concept to TH-4000, a HAP 
strategy has been developed to release EGFR inhibitors using Cobalt (III) as the hypoxia 
sensitive trigger group (figure 9) [126]. Hypoxia selective inhibition of EGFR was 
demonstrated in vitro and anticancer activity in vivo against A431 and Calu3 human tumour 
xenografts was demonstrated. HAP strategies are not only being used to deliver targeted 
small molecule but have recently been extended to include siRNA approaches. Azobenzene 
hypoxia trigger groups have been linked to siRNA for hypoxia-targeted delivery of siRNA 
along with PEGylated nanopreparations in a proof of concept study. Using multicell 
spheroids, the construct was shown to penetrate into the spheroid mass and in HeLa cells 
engineered to stably express GFP, a 30-40% down regulation of GFP was detected only 
under hypoxic (0.5% oxygen) conditions [127].  
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Concluding remarks and future directions.  
One of the most pressing unmet clinical needs is the development of therapeutic agents that 
can eradicate the hypoxic fraction of tumour cells. Despite extensive efforts to target and kill 
hypoxic cells over several decades, the need for such therapeutic strategies remains a 
significant objective. In the field of HAPs, several compounds have made it through pre-
clinical development into clinical trial but success has so far proved elusive. These failures 
however have helped shape the development and testing of new HAPs and there is now 
genuine optimism that success is imminent. Of the compounds undergoing clinical 
development, TH-302 is currently the ‘gold standard’ and the results of phase III trials are 
eagerly awaited. As described in this article, there are a number of other HAPs in clinical trial 
and behind these, there is a pipeline of other agents undergoing preclinical evaluation or 
awaiting clinical trial. Of particular interest is the development of HAP strategies designed to 
release targeted therapeutics (pioneered by TH-4000) within the hypoxic microenvironment of 
tumours and this is an exciting development. It should also be noted that HAPs represent one 
approach to targeting tumour hypoxia and other areas are being actively pursued [128]. One 
such avenue is tumour metabolism and as the biology underpinning the metabolic phenotype 
of tumour cells and the metabolic interplay between tumour and host cells under hypoxia are 
unravelled, novel therapeutic targets and strategies will emerge. Despite its lack of immediate 
success, the field of HAP development has produced a wealth of knowledge, understanding 
and expertise. It is hoped that the novel approaches to targeting hypoxia under development 
now will take note of the principles and experience gained from over 40 years of developing 
HAPs and incorporate them into the design of appropriate preclinical and clinical studies.   
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Figure legends 
Figure 1: Cartoon of the hypoxic tumour microenvironment and a generalised scheme 
for the mechanistic activation of HAPs by one and two electron reductases under 
aerobic and hypoxic conditions. The cartoon describes a central blood vessel (BV) with 
tumour cells residing various distances away from the vascular supply. Cells that reside close 
to the blood vessel are ‘happy’ in that they are receiving nutrients and oxygen but as you 
move further away from the vessel, conditions become more stressful in terms of lack of 
oxygen (hypoxia) and nutrients (together with other physiological changes such as acidic 
extracellular pH) until conditions can no longer support cell viability and necrosis occurs. As 
distance from the supporting blood vessel increases, resistance to radiotherapy and 
chemotherapy increases and the delivery of drugs to hypoxic cells becomes increasingly 
problematical. The left hand side of the cartoon describes the activation of HAPs by 1-
electron reduction pathways. The prodrug (PD) is reduced to a prodrug radical (PDR) which 
in the presence of oxygen redox cycles back to the parent compound generating superoxide 
radicals. In the absence of oxygen, the PDR is able to undergo further reactions 
(fragmentation or disproportionation) to generate the active toxic drug (T). Once the active 
drug has formed, it ideally should be able to diffuse back into the aerobic fraction and create a 
bystander effect. Even with a good bystander effect, HAPs are typically used in combination 
with radiotherapy or chemotherapy to eradicate the aerobic fraction. The right hand side of 
the figure describes the activation of HAPs by 2-electron reduction pathways. In this case 2-
electron reduction bypasses the oxygen sensitive PDR step leading directly or indirectly to the 
formation of the active toxic drug. This pathway is typically oxygen insensitive and both the 
aerobic and hypoxic fraction can theoretically be targeted. These pathways for HAP activation 
are general applicable to most HAPs although exceptions do exist. AQ4N for example is 
reduced by sequential 2 electron reduction steps that are inhibited by oxygen as described in 
the main body of the text.   
 
Figure 2: Structure of hypoxia activated prodrugs / bioreductive drugs reviewed in this 
article. The chemical structures of other compounds that fall within this group of compounds 
can be found elsewhere [27,21]. 
 
Figure 3: Reductive activation of TH-302 (Evofosfamide). In the presence of oxygen, the 
product of one electron reduction (a radical anion) is rapidly converted back to the parent 
compound. At very low oxygen concentrations, the radical anion intermediate undergoes 
fragmentation to generate bromo-isophosphoramide mustard (Br-IPM) which is a potent 
alkylating agent.  
 
Figure 4: Reductive activation of EO9 (Apaziquone). One electron reduction generates the 
semi-quinone radical which in the presence of oxygen redox cycles back to the parent 
compound. In the absence of oxygen the free radical is stabilised or undergoes a further one 
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electron reduction to generate the hydroquinone species leading to DNA damage. This 
pathway predominates in cells that have low levels of the two electron reductase NQO1 and 
very good selectivity for hypoxic cells can be achieved in cell lines that are devoid of NQO1. 
In NQO1 rich cells, two electron reduction is the dominant route and as this by passes the 
oxygen sensitive semi-quinone step, it is effectively an oxygen insensitive route of activation. 
In this case, EO9 is equally active against aerobic and hypoxic cells and selectivity depends 
largely on the expression of NQO1 in tumour cells.  
  
Figure 5: Reductive activation of AQ4N (Banoxantrone). AQ4N undergoes sequential two 
electron reduction by various cytochrome P450 (CYP) isoforms and inducible nitric oxide 
synthase to the mono-N-oxide (AQ4M) followed by a further two electron reduction to AQ4. 
Oxygen inhibits the reduction process by outcompeting AQ4N for the haem centre of CYPs 
and this mechanism differs fundamentally from other HAPs. The images are confocal images 
of cells treated with pure AQ4N and AQ4. No DNA binding is observed in cells treated with 
AQ4N but fluorescence in the nuclei of AQ4 treated cells indicates strong DNA binding 
leading to topoisomerase inhibition. The use of radiotherapy or chemotherapy to eradicate 
aerobic tumour cells causes re-oxygenation of hypoxic cells and AQ4 prevents these cells 
repopulating the tumour by virtue of its strong inhibition of topoisomerases.  
 
Figure 6: Reductive activation of PR104. The pre-prodrug PR-104 is converted to PR-104A 
by phosphatases in the systemic circulation and this then undergoes either 1 or 2 electron 
reduction. One electron reduction by enzymes such as cytochrome P450 reductase 
generates a nitro radical intermediate that can undergo rapid redox cycling back to the parent 
compound in the presence of oxygen. In the absence of oxygen, the nitro radical intermediate 
undergoes a series of reactions leading to the formation of the toxic PR-104H and PR-104M 
derivatives. Two electron reduction by aldo-ketoreductase 1C3 (AKR1C3) bypasses the 
oxygen sensitive intermediate and generates the active metabolites under aerobic and 
hypoxic conditions. In this case, selectivity may be determined by the expression of AKR1C3 
in tumour cells.  
 
Figure 7: Reductive activation of Tirapazamine (TPZ). TPZ is reduced by both one and 
two electron reductases but reduction by the former is considered to be the principle route of 
activation and selectivity for hypoxic cells. One electron reduction generates a TPZ radical 
intermediate which undergoes redox cycling back to TPZ in the presence of oxygen. Under 
hypoxic conditions, the TPZ radical intermediate undergoes further reaction to produce 
hydroxyl and benzotriazinyl radicals that ultimately lead to the induction of DNA damage. Two 
electron reduction by enzymes such as NQO1 generates metabolites with low activity and is 
regarded as a detoxification pathway. 
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Figure 8: Reductive activation of TH-4000. Reduction of TH-4000 leads to fragmentation of 
the prodrug and release of a potent inhibitor of EGFR (TH-4000E). Selectivity for hypoxic 
cells is determined by redox cycling of the Nitro radical anion species in the presence of 
oxygen.  
 
Figure 9: Chemical structures of novel HAPs currently under development. Compounds 
1 to 4 include hypoxia activated inhibitors of Chk1/Aurora A (CH-01), DNA-PK (BCCA621C), 
O6 alkylguanine DNA alkyltransferase and EGFR respectively. Details of their preclinical 
pharmacology are described elsewhere [123-126].  
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